Glioma patients with history of venous thromboembolism (VTE) treated on low molecular weight heparin (LMWH) and who decided with their physician to convert to Apixaban (oral drug) will be enrolled into our study and will collect data regarding recurrent VTE and Intracranial hemorrhage and the incidence of these events.
Primary Objectives To estimate the incidence of intracranial hemorrhage (ICH) in glioma patients with history of venous thromboembolism (VTE) after the conversion from low molecular weight heparin (LMWH) injections to oral Apixaban. Secondary Objective To estimate the incidence of recurrent VTE in glioma patients with history of venous thromboembolism after the conversion from low molecular weight heparin (LMWH) injections to oral Apixaban.
Study Type
OBSERVATIONAL
Enrollment
60
The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
Johns Hopkins
Baltimore, Maryland, United States
Intracranial Hemorrhage (ICH) event incidence rate
Observe subject to determine the incidence of ICH during standard of care (SOC) observations.
Time frame: 1 year
Deep venous thromboembolism (VTE) event incidence rate
Observe subject to determine the incidence of VTE during SOC observations.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.